On March 31, 2026, BriaCell Therapeutics Corp. filed an 8-K report with the U.S. Securities and Exchange Commission (SEC), detailing its unaudited condensed interim consolidated financial statements for the three and six month periods ending January 31, 2026. The filing includes management's discussion and analysis, which provides insights into the company's financial performance and operational activities during this period. The report highlights that BriaPro Therapeutics Corp., a subsidiary of BriaCell, has been actively engaged in pre-clinical research and development, focusing on immuno-oncology therapies. The financial statements reveal a total asset value of $176,890 as of January 31, 2026, with a significant accumulated deficit of $1,652,656 since the company's inception. The report also indicates that the company is reliant on BriaCell for financing its operations, emphasizing the importance of securing additional funding to support ongoing research and development efforts. The filing is part of BriaCell's commitment to transparency and compliance with regulatory requirements, ensuring that stakeholders are informed about the company's financial health and strategic direction.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.